JCM Webinar | NSCLC Treatment from the Early Stage to the Locally Advanced Disease in the New Era of Drugs
Meet Our Speakers
Dr. Luca Bertolaccini
Division of Thoracic Surgery, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy;
Dr Luca Bertolaccini, M.D., Ph.D., FCCP, is a thoracic surgeon in the Division of Thoracic Surgery, IEO European Institute of Oncology IRCCS, Milan (IT). He is an Associate Editor (Thoracic) of the European Journal of Cardio-Thoracic Surgery and an Editor of the Statistic Corner Column of the Journal of Thoracic Disease. He was the former Associate Editor (Thoracic) of Interactive Cardiovascular and Thoracic Surgery. He also serves on several editorial boards and is a reviewer for many scientific journals. He is a member of the European Association of Cardio-Thoracic Surgery, the European Society of Thoracic Surgeons, the European Respiratory Society, the Royal Society of Statistics, the International Society for Clinical Biostatistics, the American Association for the Advancement of Science, the American Physical Society, and the Scandinavian Society for Research in Cardiothoracic Surgery. His primary clinical interests include lung cancer surgery, minimally invasive thoracic surgery, and thoracic oncology. His research interests and leading publications focus on lung cancer surgery and biostatistics.
Prof. Dr. Paul E.Y. Van Schil
Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Belgium;
Paul Van Schil was born on July 7 1957 in Antwerp, Belgium. He graduated from medical school with outstanding honors in 1982 at Antwerp University in Belgium. After completing his training in general surgery, he became a fellow in the Department of Cardiothoracic Surgery at the Antonius Hospital, Nieuwegein, the Netherlands. His doctoral thesis was entitled “Bronchial sleeve resection for lung cancer: long-term results” (University of Nijmegen, the Netherlands, 1992).
In 1990, he became a staff member at the Department of Surgery of Antwerp University Hospital. He was the chair of the Department of Thoracic and Vascular Surgery from 2000 to 2019. Currently, he is a professor emeritus in thoracic and vascular surgery at the Faculty of Medicine and a consultant in the Department of Thoracic and Vascular Surgery of the Antwerp University Hospital.
From October 2013 to October 2014, he was the president of the European Association for Cardio-thoracic Surgery (EACTS). In 2017, he became a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC) and chair of the lung cancer domain of its Staging and Prognostic Factors Committee (SPFC). In September 2021, he was appointed president-elect of the IASLC, and in September 2023, he became president of this global organization. Currently, he is an associate editor of the Journal of Thoracic Oncology, Pulmonology, and Acta Chirurgica Belgica. His main interests are thoracic and vascular surgery with a special emphasis on lung cancer staging and therapy, lung metastases, thymoma, and mesothelioma.
Prof. Dr. Mohsen Ibrahim
Department of Medical-Surgical Science and Translational Medicine, "Sapienza" University of Rome, Rome, Italy, Department of Surgery, Division of Cardiothoracic Surgery, Washington University School of Medicine, USA;
Dr. Ibrahim is a Thoracic Surgeon, Professor of Thoracic Surgery, and Director of the Thoracic Reconstructive Program at Sant ’Andrea Hospital, University of Rome “Sapienza”, Italy. He also works as an Instructor of Surgery at Washington University in St. Louis, USA
Dr. Ibrahim’s extensive surgical experience is focused on lung transplantation, tracheo-bronchial, pulmonary artery, and vena cava reconstruction, mediastinal tumors, video-assisted thoracoscopy, robotic surgery, multimodality therapy for advanced lung cancer, and chest wall surgery.
He graduated from the University of Rome “Sapienza” in 1999 and completed the residency program of Thoracic Surgery in 2004 in the Division of Thoracic Surgery of Umberto I University Hospital. He moved to Sant’Andrea Hospital—University “La Sapienza” and accomplished his PhD in Thoracic Surgery in 2009.
He obtained, in 2010, the Evarts A. Graham Memorial Fellowship Award from the American Association for Thoracic Surgery. This gave him the opportunity to travel and visit the most important Thoracic Surgery centers in the USA and Canada (St. Louis, Boston, and Toronto).
He completed his education with a research fellowship at the Washington University in St. Louis School of Medicine in the Laboratory of Immunology where he held the title of Staff Scientist. At Washington University in St. Louis, he was also trained in the immunological and physiological methods required to evaluate innate immune responses and lung graft injury.
Prof. Dr. Ibrahim also serves as an Assistant Editor at the European Journal for Cardiothoracic Surgery; he is an active member of the Board and an examiner for the European Board for Cardiothoracic Surgery. He is the Chair of the Airway Task Force for the European Association for Cardiothoracic Surgery (EACTS).
Dr. Ibrahim also serves as President-Elect for the Italian Society for Thoracic Endoscopy.
For further details: https://www.ctsnet.org/home/mmibrahim
Prof. Dr. Isabelle Opitz
Department of Thoracic Surgery, University Hospital Zurich, Switzerland;
Prof. Dr. Isabelle Opitz is Director of the Department of Thoracic Surgery of University Hospital Zurich, Chair of the Lung Cancer Center Zurich, and Professor for Thoracic Surgery of the University of Zurich, Switzerland. She is a Past President and current director of the board of ESTS, International Director of the American Association for Thoracic Surgery, Board Member of the European Society of Thoracic Surgeons, Board Member of the International Mesothelioma Interest Group, and Associate Editor of the JTCVS. She is the Thoracic Surgery Representative for the Lung Cancer Core Group of the Swiss Association for Clinical Cancer Research (SAKK). Prof. Dr. Isabelle Opitz is one of the Chairs of the World Conference on Lung Cancer 2025 in Barcelona and a Member of the Scientific Committee for the Annual Meeting of the European Society for Medical Oncology 2025, the European Lung Cancer Conference 2025, and the Annual Meeting of the European Society of Thoracic Surgeons 2025.
To date, Prof. Dr. Isabelle Opitz has published more than 240 articles, including 155 original articles, multiple reviews, and book chapters. She has received several national and international awards for her research and has acquired more than EUR 13 million in grants for her own research. Her research mainly focuses on robotic surgery and the advanced surgical treatment of pulmonary oncology, malignant pleural mesothelioma, chronic thromboembolic pulmonary hypertension, and non-small cell lung cancer (NSCLC).
Sponsors and Partners
Organizer
The webinar on NSCLC treatment provided a comprehensive and insightful overview of the latest strategies for managing non-small cell lung cancer, from early-stage to locally advanced disease. It began with an introduction that laid the groundwork for discussions on the evolving role of surgery in early-stage NSCLC, particularly in light of new perioperative treatments. This highlighted how surgical approaches have been adapted to integrate novel therapies, aiming to improve patient outcomes. The subsequent presentation delved into the application of artificial intelligence in multidisciplinary lung cancer management, demonstrating how AI-enhanced decision-making processes had streamlined patient care and helped to personalize treatment plans by leveraging vast clinical data. A key focus of the session was the debate surrounding sublobar resections for small tumors, where the speakers examined whether this less invasive approach had offered valid oncological outcomes compared to the more extensive surgical interventions, which also led to a discussion on surgical techniques for locally advanced NSCLC, a critical topic as clinicians have been faced with complex cases requiring a careful balance between aggressive surgery and systemic therapies. The webinar concluded with a focus on challenging pulmonary resections in the era of immuno-oncology, where surgeons have adjusted their techniques to align with the immune-modulating effects of modern cancer drugs. Overall, the event underscored the importance of multidisciplinary collaboration and highlighted how the latest advances in surgery, immunotherapy, and AI have shaped the tailored treatment of NSCLC patients.
Sincerely,
Dr. Monica Casiraghi
---------------------------------------------------------
The full recording can be found below. In order to learn about future webinars, you can sign up to our newsletter by clicking “Subscribe” at the top of the page.
Prevention, Diagnosis and Treatments of Early-Stage NSCLC: New Advances and Future Prospective
Edited by Monica Casiraghi
Submission Deadline: 20 October 2024